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BACKGROUND:  True carcinosarcoma  of the breast  is  an  extremely  rare  condition,  accounting  for  0.08–0.2%
of all  breast  malignancies.
The  correct  deﬁnition  of  this  tumor  requires  both  a carcinomatous  component  and  a  malignant  non-
epithelial  component  of  mesenchymal  origin,  without  evidence  of  a  transition  zone  between  the  two
elements.
CASE  PRESENTATION:  We  present  a  case  of  a 49-year-old  woman  presenting  with  a 4  cm mass  at  the  leveliphasic metaplastic sarcomatoid
arcinoma
are breast tumours
of  her  left breast  upper-outer  quadrant  with  a  histologic  diagnosis  of true  carcinosarcoma  of the breast.
DISCUSSION:  The  most  appropriate  therapeutic  regimens  for breast  carcinosarcoma  are  still  unclear
because  of  the rarity  of  this  condition,  but  Breast  Conserving  Treatment  (BCT)  followed  by  adjuvant
chemotherapy  seems  to  provide  a prognosis  equalling  that  of usual  Invasive  Ductal  Carcinoma  of  the
breast.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Background
True carcinosarcoma of the breast is an extremely rare breast
ondition, accounting for 0.08–0.2% of all breast malignancies [1].
The correct deﬁnition of this tumor requires both a carcino-
atous component and a malignant non-epithelial component
f mesenchymal origin, without evidence of a transition zone
etween the two elements [2,3].
There is controversy about the cells of origin for this neoplasm,
ut most research leads to believe the cells are of myoepithelial
rigin, a cell with potential biphasic differentiation [4].
True carcinosarcoma of the breast should be distinguished from
etaplastic carcinoma, including spindle cell carcinoma, carci-
oma with cartilagineous or osseous metaplasia, matrix producing
arcinoma, malignant phyllodes tumor and other types of sarcoma
5,6].
The most important ﬁnding to differentiate metaplastic carci-
oma from carcinosarcoma is whether a transition zone exists.
Carcinoma of the breast can undergo spindle-cell and other
etaplasia, such as ﬁbroblastic, chondroid, osseous or osteoblas-
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tic. Although these metaplastic and inﬁltrative cancer cells form
pseudosarcomatous stroma, as if carcinomatous components are
mixed with sarcomatous components, a transition zone is always
seen between these two components [7].
Most true carcinosarcoma of the breast shows no expression of
estrogen and progesterone receptors and HER2-neu,with a so called
“triple negative” pattern [8].
The 5-year survival rate of true carcinosarcoma is 49%, worst
than other metaplastic breast cancers. Treatment strategies for
true breast carcinosarcoma resemble those for usual breast can-
cer [9–11]. Carcinosarcoma metastasize by the lymphogenous
route [3], therefore axillary examination with sentinel node biopsy
and/or axillary dissection is suggested. This tumor also shows
hematogenous metastases: pleural and pulmonary more com-
monly than skeletal, liver or brain metastases [10,11].
2. Case presentation
We report the case of a 49-year-old woman presenting a mass
at the level of her left breast which rapidly grew in the period of 2
months.
Physical examination showed a ﬁrm mass measuring 4 cm in
greatest dimension with irregular margins in the upper outer quad-
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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oig. 1. Ultrasonography shows a 40 mm hypoechoic non homogenous mass with
rregular margins.
ant of the left breast without enlarged palpable lymphnodes in the
molateral axilla.
Ultrasonography showed a solid hypoechoic 4 cm non homoge-
ous mass with irregular margins (Fig. 1).
Mammography revealed a radiopaque lesion with irregular
oundaries at the level of the left upper-outer quadrant (Fig. 2).
We  performed a pre-operative Ultrasound-guided Fine-Needle
spiration Cytology (US-FNAC) that showed hystiocytes and
pithelial cells with moderate nuclear atypia surrounded by blood
nd necrotic cells, suggesting a surgical biopsy with intraoperatory
istological examination.
We  performed an excisional biopsy of the mass with the his-
ological diagnosis of carcinosarcoma (Fig. 3), followed by a wide
xcision (in relation to the favourable tumor/breast ratio) and sen-
inel lymphnode biopsy.
In gross description the mass measured 4 × 3 cm,  revealing areas
ith epithelial and mesenchymal characteristics on histopatholog-
cal examination.
Immunohistochemistry showed Ki67 proliferation index of
0–80% in both epithelial and mesenchimal component.
All tumor cells were negative for estrogen, progesterone and
-erb-B2.
Carcinomatous component was positive for low and high molec-
lar weight cytocheratines (pancytocheratine AE1/AE3, CK 7, CK
/18, CK 34 beta E 12).
Sarcomatous component was negative for cytocheratines and
ositive for vimentine, muscle-speciﬁc actine, p63 and focally for S-
00; Vimentine and p63 were positive in the epithelial component
s well. CD34 reveals a particular angiogenesis in the neoplasia.
No residual tumor was found in the excision area in the quad-
antectomy specimen.
Histopathological examination of the sentinel lymph node was
onsistent with ‘reactive hyperplasia’.
No evidence of distant disease was found at systemic imaging
nvestigations.
The patient received adjuvant radiotherapy (total dose of 50 Gy)
nd chemotherapy with Anthracyclines and Taxanes. She is now in
er 4th year of follow-up with no evidence of disease.
. Discussion
The clinical and pathologic features of true carcinosarcoma
f the breast are important to distinguish this rare condition
rom other types of uncommon breast malignancies such as spin-
le cell carcinoma, matrix producing carcinoma, ﬁbrosarcoma,
steosarcoma, malignant ﬁbrous histiocytoma, phylloides tumorFig. 2. (A and B). A high-density irregular mass in the left upper outer quadrant can
be  seen at mammography. (A) Oblique view; (B) Craniocaudal view.
and stromal sarcoma as their behavior, response to treatment and
survival rates differ greatly [9].
Clinical features of breast carcinosarcoma are similar to those of
invasive ductal carcinoma [10–12]. Recurrence can be rapid as the
primary tumor is aggressive, thus mandating close interval follow-
up after resection. Pulmonary metastasis is more common than
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rain, skeletal or hepatic metastasis, and the prognosis for these
etastatic patients is poor.
Outcomes for local recurrences are somewhat improved when
urgical resection is achievable. In general, the recommended treat-
ent options have followed the established NCCN guidelines for
atients with invasive breast cancer. In the majority of the reported
ases, surgery with sentinel lymphnode biopsy or axillary node
issection was performed, followed by post-operative chemother-
py and radiation therapy in various combinations. Evaluation
f patients with breast carcinosarcomas includes analysis of the
xpression of various receptors on the primary tumor.
The HER1/EGFR receptor is reported to be over-expressed in the
ajority of carcinosarcomas of the breast. The results may  then be
tilized to tailor the adjuvant therapy based upon these ﬁndings.
New treatment opportunities may  exist with the development
f agents targeting the EGFR receptor such as Geﬁtinib (ZD1839,
ressa) and Cetuximab (Erbitux) [13,14].
Obtaining an accurate diagnosis of true carcinosarcoma is essen-
ial in order to optimally tailor adjuvant therapy towards this
ggressive breast cancer subtype. This requires an interdisciplinary
pproach to treatment, with the involvement of the entire oncol-
gy team comprised of the primary care physician, the pathologists,
urgical oncologist, radiation oncologist, medical oncologist, and
he supporting nursing and research staff. Adjuvant chemotherapy
s generally recommended utilizing established NCCN guidelines
or the more common types of breast cancer.
By improving our understanding of true carcinosarcoma of
he breast, we may  provide such patients with novel and poten-
ially effective treatment options that will ultimately translate into
mproved overall outcomes.
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